Cigna earnings beat by $0.04, revenue topped estimates
On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $13.00 price target for Lifeward (NASDAQ:LFWD), representing significant upside from the current price of $1.31. The stock is trading near its 52-week low, far below its peak of $6.00. The endorsement followed Lifeward’s announcement last Tuesday of its fourth-quarter financial results for 2024 and a corporate update. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates. The company’s management has outlined its strategy for 2025, aiming to broaden the market reach of its ReWalk Personal product, targeting coverage by the Centers for Medicare & Medicaid Services (CMS), workers compensation insurance, and U.S. commercial insurers.
Despite challenges with CMS reimbursement times, Lifeward anticipates improvements in the processing period. The company reported that more than 110 ReWalk cases are in the evaluation phase for deployment in the U.S., with an additional 44 cases in Germany as of the end of the fourth quarter of 2024. InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.08, indicating sufficient resources to fund its growth initiatives. Furthermore, Lifeward’s AlterG product concluded the year with a significant backlog of 25 systems, which are expected to be placed in the first half of 2025.
The financial results revealed that Lifeward achieved $7.5 million in revenue for the fourth quarter of 2024, marking a 23% quarter-over-quarter increase from $6.1 million in the third quarter. This growth contributes to an impressive 85.24% year-over-year revenue increase, according to InvestingPro data, demonstrating strong market momentum despite the company’s modest $13.92 million market capitalization. Based on these figures and the company’s trajectory, H.C. Wainwright projects that Lifeward’s total revenues will surge to $336.5 million in 2032 from $29.0 million in 2025.
The analyst from H.C. Wainwright expressed confidence in the company’s future, especially with the strong performance of AlterG, which is anticipated to make a significant contribution to Lifeward’s growth in 2025 and the years to follow. For deeper insights into Lifeward’s growth potential and comprehensive analysis, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which includes additional financial metrics and expert analysis. The maintained Buy rating and price target reflect the firm’s positive outlook on Lifeward’s stock performance and business prospects.
In other recent news, Lifeward Ltd reported its fourth-quarter 2024 earnings, revealing a significant earnings miss with an EPS of -$0.38, falling short of the forecasted -$0.19. The company also reported a revenue shortfall, bringing in $7.5 million compared to the anticipated $10.3 million. Despite these challenges, Lifeward achieved a full-year 2024 revenue of $25.7 million, marking an 85% increase from the previous year. The company faced an operating loss, largely due to a $9.8 million intangible asset impairment. For 2025, Lifeward projects revenue between $28 million and $30 million, with plans to reduce quarterly operating losses. In related developments, Lifeward has established strategic partnerships, including an exclusive agreement with CoreLife for workers’ compensation claims, aimed at improving efficiency and market reach. Additionally, the company anticipates FDA clearance for its 7th generation ReWalk in the first half of 2025, which could drive future growth. Analysts from firms like Laidlaw and Lake Street Capital Markets have engaged with the company, seeking clarity on these recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.